Experimental HIV Drugs
Experimental HIV Drugs
ICAAC 2014: PK Study Shows Feasibility of Long-acting Integrase Inhibitor Cabotegravir
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 09 September 2014 00:00
- Written by Liz Highleyman
A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).
ICAAC 2014: New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 08 September 2014 00:00
- Written by Liz Highleyman
An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, according to a study presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.
Janssen and ViiV to Develop NRTI-free Single-tablet Regimen
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 19 June 2014 00:00
- Written by Janssen
Janssen R&D and ViiV Healthcare announced last week that they will collaborate on the development of a dual single-tablet regimen containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the new integrase inhibitor dolutegravir, to be used as maintenance therapy for people who achieve viral suppression using a traditional regimen.
FDA Approves ViiV Single-Tablet Regimen Containing Dolutegravir
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 22 August 2014 00:00
- Written by ViiV Healthcare
ViiV Healthcare announced this week that the U.S. Food and Drug Administration (FDA) has approved its all-in-1 antiretroviral fixed-dose combination pill containing the HIV integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (the drugs in Epzicom or Kivexa). The new coformulation -- with the brand name Triumeq -- is the first single-tablet regimen that does not contain tenofovir and emtricitabine, making it an option for people with impaired kidney function. HLA-B*5701 genetic screening should be done prior to starting Triumeq to test for abacavir hypersensitivity. [Editor's note: On September 3 ViiV announced that the European Commission has also approved Triumeq.]
CROI 2014: New NNRTI Doravirine Matches Efavirenz for First-line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 10 March 2014 00:00
- Written by Liz Highleyman
The next-generation non-nucleoside reverse transcriptase inhibitor doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/emtricitabine (the drugs in Truvada) in a dose-finding study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.
More Articles...
- CROI 2014: Novel 2-Drug Maintenance Combo Works Well, Stage Set for Long-lasting Injectables
- CROI 2014: Long-Acting HIV Drugs for Maintenance Therapy [VIDEO]
- CROI 2014: Raltegravir Works as Well as Tenofovir for HIV Treatment [VIDEO]
- CROI 2014: HIV Attachment Inhibitor BMS-663068 Shows Good Safety and Efficacy in Phase 2b
Web Design and Development by